Improvements in the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC)
have lagged behind advances made in the treatment of many other malignancies over the …

Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is
the fourth leading cause of cancer-related deaths in the world. Due to the broad …

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-
quality multiphase imaging can help to preoperatively distinguish between patients eligible …

Objective: To identify predictive factors associated with operative morbidity, mortality, and
survival outcomes in patients with borderline resectable (BR) or locally advanced (LA) …

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and
management of adenocarcinomas of the exocrine pancreas and are intended to assist with …

Objective: The aim of the study was to identify the survival of patients with locally advanced
pancreatic cancer (LAPC) and assess the effect of surgical resection after neoadjuvant …

The development of diagnostic and therapeutic nanoparticles for biomedical applications is
of broad current interest in science, engineering, and medicine. The fundamental basis is …

Background This position statement was developed to expedite a consensus on definition
and treatment for borderline resectable pancreatic ductal adenocarcinoma (BRPC) that …

Purpose To provide evidence-based recommendations to oncologists and others on
potentially curative therapy for patients with localized pancreatic cancer. Methods ASCO …

Methods: Analyses were carried out to assess the association between clinical
characteristics and margin involvement as well as the effects of individual margin …